An Urgent Message from NovaBay’s CEO: Why a FOR Vote is Crucial at the Upcoming Reconvened Special Meeting
Letter to Stockholders
To My Fellow Stockholders,
You have the opportunity to approve a transaction that I fully support and that our Board of Directors unanimously believes is in your best interest. Through the proposed sale of NovaBay’s eyecare business and Avenova® brand to PRN Physician Recommended, we have the chance to take a step that will position NovaBay for even greater success in the future.
Over the years, we have worked tirelessly to build NovaBay into a leading pharmaceutical company focused on developing and commercializing products to address unmet medical needs. The sale of our eyecare business will allow us to streamline our operations and concentrate our efforts on our core areas of strength, such as our wound care and urinary catheter products.
By divesting the eyecare business, we will not only be able to reduce costs and improve profitability, but also enhance our ability to invest in research and development to drive future growth. This transaction will enable NovaBay to strengthen its balance sheet and focus on bringing innovative solutions to market that can make a meaningful difference in the lives of patients.
As the CEO of NovaBay, I urge you to vote FOR this transaction at the upcoming reconvened special meeting. Your support is crucial to the success of this strategic move, which will unlock value for our stockholders and pave the way for a brighter future for NovaBay.
Thank you for your continued support and trust in NovaBay’s vision and leadership.
How this will affect you:
The sale of NovaBay’s eyecare business and Avenova® brand to PRN Physician Recommended will allow the company to focus on its core products, potentially leading to greater innovation and development in areas that may directly impact you. By streamlining operations and reducing costs, NovaBay may be able to provide more effective solutions for medical needs, ultimately benefiting patients and consumers like you.
How this will affect the world:
NovaBay’s decision to sell its eyecare business and concentrate on core areas of strength may have broader implications for the pharmaceutical industry as a whole. By strengthening its balance sheet and focusing on research and development, NovaBay could set a precedent for other companies to prioritize innovation and patient-centric solutions, leading to advancements in healthcare and improved outcomes for people around the world.
Conclusion
The upcoming reconvened special meeting presents a crucial opportunity for NovaBay and its stockholders to approve a transaction that will shape the company’s future. By voting FOR the sale of the eyecare business, you are supporting a strategic move that will enhance NovaBay’s focus, drive innovation, and unlock value for stakeholders. Your vote matters, and your support is essential to ensuring the continued success and growth of NovaBay. Thank you for your consideration and dedication to NovaBay’s mission.
